Daniel D. Shoemaker
2018
In 2018, Daniel D. Shoemaker earned a total compensation of $1.3M as Chief Scientific Officer at Fate Therapeutics, a 67% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $127,750 |
|---|---|
| Option Awards | $842,338 |
| Salary | $365,000 |
| Total | $1,335,088 |
Shoemaker received $842.3K in option awards, accounting for 63% of the total pay in 2018.
Shoemaker also received $127.8K in non-equity incentive plan and $365K in salary.
Rankings
In 2018, Daniel D. Shoemaker's compensation ranked 7,747th out of 14,244 executives tracked by ExecPay. In other words, Shoemaker earned more than 45.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,747 out of 14,244 | 46th |
Division Manufacturing | 3,022 out of 5,759 | 48th |
Major group Chemicals And Allied Products | 1,130 out of 2,122 | 47th |
Industry group Drugs | 953 out of 1,811 | 47th |
Industry Biological Products, Except Diagnostic Substances | 178 out of 339 | 48th |
Source: SEC filing on March 22, 2019.
Shoemaker's colleagues
We found three more compensation records of executives who worked with Daniel D. Shoemaker at Fate Therapeutics in 2018.